Exp Clin Endocrinol Diabetes 2013; 121(05): 300-305
DOI: 10.1055/s-0032-1331695
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

The Role of Type II Deiodinase Polymorphisms in Clinical Management of Hypothyroid Patients Treated with Levothyroxine

S. I. Al-azzam
1   Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan
,
A. M. Alkhateeb
2   Department of Biotechnology and Genetic Eng., Faculty of Science and Art, Jordan University of Science and Technology, Irbid, Jordan
,
O. Al-Azzeh
1   Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan
,
K. H. Alzoubi
1   Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan
,
O. F. Khabour
3   Department of Medical Laboratory Sciences, Faculty Applied Medical Sciences, Jordan University of Science and ­Technology, Irbid, Jordan
› Author Affiliations
Further Information

Publication History

received 05 February 2012
first decision 26 May 2012

accepted 22 November 2012

Publication Date:
17 January 2013 (online)

Abstract

Study Objective:

Several factors can affect achieving the goals with levothyroxine (L-T4) therapy. This study investigates the clinical and biochemical response to L-T4 replacement therapy in hypothyroid patients in correlation with genetic variation in Deiodinase type || (DIO2) gene.

Design and setting:

This is a cross-sectional correlation study. The setting was the diabetes and endocrinology clinics at 2 Jordanian Hospitals.

Methodology:

Patients with primary hypothyroidism who are controlled on stable L-T4 replacement therapy were recruited and thyroid function test was performed. Genetic analysis to detect 4 single nucleotide polymorphisms (SNPs) rs225011, rs7140952, rs225012 and rs2839858 in DIO2 gene was carried out using the polymerase chain reaction-based restriction fragment length polymorphism assay (PCR-RFLP).

Results:

There was no correlation between the 4 SNPs in DIO2 gene and replacement doses of L-T4, whereas a statistical significance was found between rs7140952 and central obesity (P<0.05), and systolic and diastolic blood pressure (P<0.05). The dose of L-T4 was associated with lower levels of TSH, fT4, central obesity, body mass index and waist circumference.

Conclusion:

While L-T4 dose is associated with several positive effects on hypothyroid patients, none of the examined SNPs in DIO2 is correlated with replacement doses of the drug. However, rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity.

 
  • References

  • 1 Todd CH. Management of thyroid disorders in primary care: challenges and controversies. Postgrad Med J 2009; 85: 655-659
  • 2 Vaidya B, Pearce SH. Management of hypothyroidism in adults. BMJ 2008; 337: a801
  • 3 Baskin HJ, Cobin RH, Duick DS et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002; 8: 457-469
  • 4 Checchi S, Montanaro A, Pasqui L et al. L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J Clin Endocrinol Metab 2008; 93: 465-469
  • 5 Jonklaas J. Gender and Age Differences in Levothyroxine Dose Requirement. Endocrine Practice 2009; 15: 1-23
  • 6 Peeters RP, van Toor H, Klootwijk W et al. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab 2003; 88: 2880-2888
  • 7 Kim BW, Bianco AC. For some, L-thyroxine replacement might not be enough: a genetic rationale. J Clin Endocrinol Metab 2009; 94: 1521-1523
  • 8 Torlontano M, Durante C, Torrente I et al. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab 2008; 93: 910-913
  • 9 Guo TW, Zhang FC, Yang MS et al. Positive association of the DIO2 (deiodinase type 2) gene with mental retardation in the iodine-deficient areas of China. J Med Genet 2004; 41: 585-590
  • 10 Peeters RP, van den Beld AW, Attalki H et al. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. Am J Physiol Endocrinol Metab 2005; 289: E75-E81
  • 11 Heemstra KA, Soeters MR, Fliers E et al. Type 2 iodothyronine deiodinase in skeletal muscle: effects of hypothyroidism and fasting. J Clin Endocrinol Metab 2009; 94: 2144-2150
  • 12 Schneider MJ, Fiering SN, Pallud SE et al. Targeted disruption of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of pituitary resistance to T4. Mol Endocrinol 2001; 15: 2137-2148
  • 13 Maia AL, Kim BW, Huang SA et al. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 2005; 115: 2524-2533
  • 14 Panicker V, Saravanan P, Vaidya B et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 2009; 94: 1623-1629
  • 15 He B, Li J, Wang G et al. Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 986-990
  • 16 Celi FS, Canettieri G, Mentuccia D et al. Structural organization and chromosomal localization of the human type II deiodinase gene. Eur J Endocrinol 2000; 143: 267-271
  • 17 Nair S, Muller YL, Ortega E et al. Association Analyses of Variants in the DIO2 Gene with Early-Onset Type 2 Diabetes Mellitus in Pima Indians. Thyroid 2012; 22: 80-87
  • 18 Gharibeh MY, Al Tawallbeh GM, Abboud MM et al. Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients. Diabetes Metab 2010; 36: 443-449
  • 19 Hueston WJ. Treatment of hypothyroidism. Am Fam Physician 2001; 64: 1717-1724
  • 20 Medline database [database on the Internet] 2010 [cited June 2010]. Available from www.ncbi.nlm.gov/SNP/
  • 21 The human genome browser at UCSC Genome. [database on the Internet]. USCS Genome Bioinformatics [cited June 2010]. Available from: genome.uscs.edu
  • 22 Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S. (eds.). Bioinformatics Methods and Protocols: Methods in Molecular Biology [database on the Internet]. 2000. [cited 10/26/2009]. Available from: http://fokker.wi.mit.edu/primer3/
  • 23 Vincze T, Posfai J, Roberts RJ. NEBcutter: A program to cleave DNA with restriction enzymes. Nucleic Acids Res 2003; 31: 3688-3691
  • 24 Maps sites for restriction enzymes, a.k.a. restriction endonucleases, in DNA sequences [database on the Internet] 2010 [cited July 2010]. Available from www.restrictionmapper.org
  • 25 Heemstra KA, Hoftijzer HC, van der Deure WM et al. Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis. Clin Endocrinol (Oxf) 2009; 71: 279-283
  • 26 Mentuccia D, Proietti-Pannunzi L, Tanner K et al. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes 2002; 51: 880-883
  • 27 Dora JM, Machado WE, Rheinheimer J et al. Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study and meta-analysis. Eur J Endocrinol 2010; 163: 427-434
  • 28 Rizk N, Amin M, Yousef M. A pilot study on metabolic syndrome and its associated features among Qatari schoolchildren. Int J Gen Med 2011; 4: 521-525
  • 29 Fiorito M, Torrente I, De Cosmo S et al. Interaction of DIO2 T92A and PPARgamma2 P12A polymorphisms in the modulation of metabolic syndrome. Obesity (Silver Spring) 2007; 15: 2889-2895
  • 30 Medici M, van der Deure WM, Verbiest M et al. A large-scale association analysis of 68 thyroid hormone pathway genes with serum TSH and FT4 levels. Eur J Endocrinol 2011; 164: 781-788
  • 31 van der Deure WM, Peeters RP, Visser TJ. Molecular aspects of thyroid hormone transporters, including MCT8, MCT10, and OATPs, and the effects of genetic variation in these transporters. J Mol Endocrinol 2010; 44: 1-11
  • 32 Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J 2011; 5: 76-84
  • 33 Ganie MA, Laway BA, Wani TA et al. Association of subclinical hypothyroidism and phenotype, insulin resistance, and lipid parameters in young women with polycystic ovary syndrome. Fertil Steril 2011; 95: 2039-2043
  • 34 Asvold BO, Bjoro T, Vatten LJ. Association of serum TSH with high body mass differs between smokers and never-smokers. J Clin Endocrinol Metab 2009; 94: 5023-5027
  • 35 Alevizaki M, Saltiki K, Voidonikola P et al. Free thyroxine is an independent predictor of subcutaneous fat in euthyroid individuals. Eur J Endocrinol 2009; 161: 459-465
  • 36 Ruhla S, Weickert MO, Arafat AM et al. A high normal TSH is associated with the metabolic syndrome. Clin Endocrinol (Oxf) 2010; 72: 696-701
  • 37 Jordan in Numbers. [Internet]. Amman, Jordan, Department of statistics 2007 Available from http://www.dos.gov.jo